27515250|t|A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia. Final results of the GIMEMA LAL 0904 study
27515250|a|In the GIMEMA LAL 0904 protocol, adult Ph+ acute lymphoblastic leukemia patients were treated with chemotherapy for induction and consolidation, followed by maintenance with imatinib. The protocol was subsequently amended and imatinib was incorporated in the induction and post - remission phase together with chemotherapy. Due to the toxicity of this combined approach, the protocol was further amended to a sequential scheme based on imatinib plus steroids as induction, followed by consolidation with chemotherapy plus imatinib and, when applicable, by a hematopoietic stem cell transplant. Fifty-one patients (median age: 45.9 years) were enrolled in the final sequential protocol, hereby reported. At the end of induction (day +50), 96% of evaluable patients (n=49) achieved a complete hematologic remission; after consolidation, all were in complete hematologic remission. No deaths in induction were recorded. Overall survival and disease-free survival at 60 months are 48.8% and 45.8%, respectively. At day +50 (end of the imatinib induction), a log - reduction of BCR-ABL1 levels >1.3 was associated with a significantly more prolonged disease-free survival (55.6%, C.I. 95%: 39.0-79.3 vs 20%, C.I. 95%: 5.8-69.1; p =0.03), overall survival (59.1%, C.I. 95%: 42.3-82.6 vs 20%, C.I. 95%: 5.8-69.1, p =0.02) and lower relapse incidence (20.5%, C.I. 95%: 7.2-38.6 vs 60.0%, C.I. 95%: 21.6-84.3, p =0.01). Mean BCR-ABL1 levels remained significantly higher in patients who subsequently relapsed. Finally, BCR-ABL1p190 patients showed a significantly faster molecular response than BCR-ABL1p210 patients (p =0.023). Thought the study was not powered to evaluate the role of allogeneic stem cell transplant, allografting positively impacted on overall survival and disease-free survival. A sequential approach with imatinib alone in induction, consolidated by chemotherapy plus imatinib followed by a stem cell transplant is a feasible, well-tolerated and effective strategy for adult Ph+ acute lymphoblastic leukemia, leading to the best long-term survival rates so far reported. Trial ID: NCT00458848.
27515250	2	12	sequential	T080	C1705294
27515250	13	21	approach	T082	C0449445
27515250	27	35	imatinib	T109,T121	C0935989
27515250	37	49	chemotherapy	T061	C3665472
27515250	54	64	transplant	T033	C3841811
27515250	69	74	adult	T100	C0001675
27515250	75	107	Ph+ acute lymphoblastic leukemia	T191	C1960397
27515250	109	114	Final	T079	C3853528
27515250	115	122	results	T033	C2825142
27515250	130	151	GIMEMA LAL 0904 study	T059	C0947630
27515250	159	183	GIMEMA LAL 0904 protocol	T170	C1507394
27515250	185	190	adult	T100	C0001675
27515250	191	223	Ph+ acute lymphoblastic leukemia	T191	C1960397
27515250	224	232	patients	T101	C0030705
27515250	238	245	treated	T169	C1522326
27515250	251	263	chemotherapy	T061	C3665472
27515250	268	277	induction	T061	C0857127
27515250	282	295	consolidation	T061	C1511484
27515250	309	320	maintenance	T052	C0024501
27515250	326	334	imatinib	T109,T121	C0935989
27515250	340	348	protocol	T170	C1507394
27515250	366	373	amended	T080	C1691222
27515250	378	386	imatinib	T109,T121	C0935989
27515250	391	403	incorporated	T169	C0243126
27515250	411	420	induction	T061	C0857127
27515250	425	429	post	T079	C0687676
27515250	432	447	remission phase	T033	C0544452
27515250	462	474	chemotherapy	T061	C3665472
27515250	487	495	toxicity	T037	C0600688
27515250	504	512	combined	T080	C0205195
27515250	513	521	approach	T082	C0449445
27515250	527	535	protocol	T170	C1507394
27515250	548	555	amended	T080	C1691222
27515250	561	571	sequential	T080	C1705294
27515250	588	596	imatinib	T109,T121	C0935989
27515250	602	610	steroids	T109	C0038317
27515250	614	623	induction	T061	C0857127
27515250	637	650	consolidation	T061	C1511484
27515250	656	668	chemotherapy	T061	C3665472
27515250	674	682	imatinib	T109,T121	C0935989
27515250	710	744	hematopoietic stem cell transplant	T061	C0472699
27515250	756	764	patients	T101	C0030705
27515250	773	776	age	T032	C0001779
27515250	783	788	years	T079	C1510829
27515250	811	816	final	T079	C3853528
27515250	817	827	sequential	T080	C1705294
27515250	828	836	protocol	T170	C1507394
27515250	845	853	reported	T058	C0700287
27515250	869	878	induction	T061	C0857127
27515250	907	915	patients	T101	C0030705
27515250	943	964	hematologic remission	T033	C0544452
27515250	972	985	consolidation	T061	C1511484
27515250	1008	1029	hematologic remission	T033	C0544452
27515250	1034	1040	deaths	T033	C1306577
27515250	1044	1053	induction	T061	C0857127
27515250	1059	1067	recorded	T080	C2355580
27515250	1077	1085	survival	T052	C0038952
27515250	1090	1111	disease-free survival	T081	C0242793
27515250	1118	1124	months	T079	C0439231
27515250	1163	1166	day	T079	C0439228
27515250	1183	1191	imatinib	T109,T121	C0935989
27515250	1192	1201	induction	T061	C0857127
27515250	1206	1209	log	T081	C2986775
27515250	1212	1221	reduction	T080	C0392756
27515250	1225	1233	BCR-ABL1	T116,T123	C0004891
27515250	1234	1240	levels	T080	C0441889
27515250	1250	1265	associated with	T080	C0332281
27515250	1268	1286	significantly more	T081	C4055637
27515250	1287	1296	prolonged	T079	C0439590
27515250	1297	1318	disease-free survival	T081	C0242793
27515250	1327	1330	C.I	T081	C0009667
27515250	1355	1358	C.I	T081	C0009667
27515250	1375	1376	p	T081	C1709380
27515250	1385	1401	overall survival	T081	C4086681
27515250	1410	1413	C.I	T081	C0009667
27515250	1438	1441	C.I	T081	C0009667
27515250	1458	1459	p	T081	C1709380
27515250	1471	1476	lower	T080	C0205251
27515250	1477	1484	relapse	T067	C0035020
27515250	1485	1494	incidence	T081	C0021149
27515250	1503	1506	C.I	T081	C0009667
27515250	1532	1535	C.I	T081	C0009667
27515250	1553	1554	p	T081	C1709380
27515250	1568	1576	BCR-ABL1	T116,T123	C0004891
27515250	1577	1583	levels	T080	C0441889
27515250	1593	1613	significantly higher	T081	C4055637
27515250	1617	1625	patients	T101	C0030705
27515250	1643	1651	relapsed	T079	C0205336
27515250	1662	1674	BCR-ABL1p190	T116,T123	C0004891
27515250	1675	1683	patients	T101	C0030705
27515250	1693	1706	significantly	T078	C0750502
27515250	1707	1713	faster	T080	C0456962
27515250	1714	1732	molecular response	T033	C4054479
27515250	1738	1750	BCR-ABL1p210	T116,T123	C0004891
27515250	1751	1759	patients	T101	C0030705
27515250	1761	1762	p	T081	C1709380
27515250	1784	1789	study	T062	C0008972
27515250	1809	1817	evaluate	T058	C0220825
27515250	1830	1861	allogeneic stem cell transplant	T061	C4255274
27515250	1863	1875	allografting	T061	C0040739
27515250	1876	1886	positively	T033	C3843166
27515250	1887	1895	impacted	T169	C0333125
27515250	1899	1915	overall survival	T081	C4086681
27515250	1920	1941	disease-free survival	T081	C0242793
27515250	1945	1955	sequential	T080	C1705294
27515250	1956	1964	approach	T082	C0449445
27515250	1970	1978	imatinib	T109,T121	C0935989
27515250	1988	1997	induction	T061	C0857127
27515250	1999	2011	consolidated	T061	C1511484
27515250	2015	2027	chemotherapy	T061	C3665472
27515250	2033	2041	imatinib	T109,T121	C0935989
27515250	2056	2076	stem cell transplant	T061	C1504389
27515250	2111	2120	effective	T080	C1704419
27515250	2121	2129	strategy	T169	C0449851
27515250	2134	2139	adult	T100	C0001675
27515250	2140	2172	Ph+ acute lymphoblastic leukemia	T191	C1960397
27515250	2194	2203	long-term	T079	C0443252
27515250	2204	2218	survival rates	T081	C0038954
27515250	2226	2234	reported	T058	C0700287